相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Abametapir for the Treatment of Head Lice: A Drug Review
Alexander D. Woods et al.
ANNALS OF PHARMACOTHERAPY (2022)
Vadadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, for treatment of anemia of chronic kidney disease: two randomized Phase 2 trials in Japanese patients
Masaomi Nangaku et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2021)
FDA Approval Summary: Selpercatinib for the Treatment of Lung and Thyroid Cancers with RET Gene Mutations or Fusions
Diana Bradford et al.
CLINICAL CANCER RESEARCH (2021)
Bempedoic Acid: A New Tool in the Battle Against Hyperlipidemia
Jason Powell et al.
CLINICAL THERAPEUTICS (2021)
Enarodustat: First Approval
Anthony Markham
DRUGS (2021)
Systemic therapy of advanced/metastatic gastrointestinal stromal tumors: an update on progress beyond imatinib, sunitinib, and regorafenib
Mahmoud Mohammadi et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2021)
Long-Acting Injectables Come of Age to Change the HIV Therapeutic Landscape and the Lives of Persons with HIV
Kimberly Y. Smith
AIDS RESEARCH AND HUMAN RETROVIRUSES (2021)
Berotralstat: First Approval
Arnold Lee
DRUGS (2021)
Targeted Therapy Approaches for MET Abnormalities in Non-Small Cell Lung Cancer
Edward B. Garon et al.
DRUGS (2021)
Tirbanibulin: First Approval
Anthony Markham et al.
DRUGS (2021)
Innovation in the discovery of the HIV-1 attachment inhibitor temsavir and its phosphonooxymethyl prodrug fostemsavir
Tao Wang et al.
MEDICINAL CHEMISTRY RESEARCH (2021)
Investigational topical anticholinergics in clinical development for the treatment of hyperhidrosis
Stamatios Gregoriou et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2021)
Phase 3 Trials of Tirbanibulin Ointment for Actinic Keratosis
Andrew Blauvelt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Stereocontrolled Synthesis of Delgocitinib, a JAK Inhibitor for the Treatment of Atopic Dermatitis
Hiromu Takiguchi et al.
ORGANIC PROCESS RESEARCH & DEVELOPMENT (2021)
Development of a Robust and Scalable Process for the Large-Scale Preparation of Vadadustat
Biyue Lin et al.
ORGANIC PROCESS RESEARCH & DEVELOPMENT (2021)
Boron neutron capture therapy using cyclotron-based epithermal neutron source and borofalan (10B) for recurrent or locally advanced head and neck cancer (JHN002): An open-label phase II trial
Katsumi Hirose et al.
RADIOTHERAPY AND ONCOLOGY (2021)
Risdiplam, the First Approved Small Molecule Splicing Modifier Drug as a Blueprint for Future Transformative Medicines
Hasane Ratni et al.
ACS MEDICINAL CHEMISTRY LETTERS (2021)
Profile of Daprodustat in the Treatment of Renal Anemia Due to Chronic Kidney Disease
Taisuke Ishii et al.
THERAPEUTICS AND CLINICAL RISK MANAGEMENT (2021)
Resuscitative Effect of Centhaquine (Lyfaquin(R)) in Hypovolemic Shock Patients: A Randomized, Multicentric, Controlled Trial
Anil Gulati et al.
ADVANCES IN THERAPY (2021)
Surufatinib: First Approval
Yahiya Y. Syed
DRUGS (2021)
New drug approvals for 2020: Synthesis and clinical applications
Shuo Yuan et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2021)
Therapeutic interventions for spinal muscular atrophy: preclinical and early clinical development opportunities
Laurent Servais et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2021)
Synthetic Approaches to the New Drugs Approved during 2019
Andrew C. Flick et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
Designation Products: Boron Neutron Capture Therapy for Head and Neck Carcinoma
Hitoshi Kanno et al.
ONCOLOGIST (2021)
Centhaquine Restores Renal Blood Flow and Protects Tissue Damage After Hemorrhagic Shock and Renal Ischemia
Amaresh K. Ranjan et al.
FRONTIERS IN PHARMACOLOGY (2021)
Oliceridine: A Novel Drug for the Management of Moderate to Severe Acute Pain - A Review of Current Evidence
Hon Sen Tan et al.
JOURNAL OF PAIN RESEARCH (2021)
Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study
Chloe Orkin et al.
Lancet HIV (2021)
A phase III, 52-week, open-label study to evaluate the safety and efficacy of 5% sofpironium bromide (BBI-4000) gel in Japanese patients with primary axillary hyperhidrosis
Tomoko Fujimoto et al.
JOURNAL OF DERMATOLOGY (2021)
Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study
Justin F. Gainor et al.
LANCET ONCOLOGY (2021)
Avapritinib for Systemic Mastocytosis
Prithviraj Bose et al.
EXPERT REVIEW OF HEMATOLOGY (2021)
Ripretinib in gastrointestinal stromal tumor: the long-awaited step forward
M. Julia Lostes-Bardaji et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2021)
Inhibitors targeting Bruton's tyrosine kinase in cancers: drug development advances
Tingyu Wen et al.
LEUKEMIA (2021)
A Stable and Cleavable O-Linked Spacer for Drug Delivery Systems
Kei Ito et al.
CHEMICAL & PHARMACEUTICAL BULLETIN (2020)
Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study
Sagar Lonial et al.
LANCET ONCOLOGY (2020)
Towards personalized treatment for early stage HER2-positive breast cancer
Kristina Goutsouliak et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2020)
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
R. K. Murthy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Site-Selective C-H Alkylation of Piperazine Substrates via Organic Photoredox Catalysis
Joshua B. McManus et al.
ORGANIC LETTERS (2020)
A Review of the Efficacy and Tolerability of Bempedoic Acid in the Treatment of Hypercholesterolemia
Stephanie Niman et al.
AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS (2020)
Biochemical characterization of tirabrutinib and other irreversible inhibitors of Bruton's tyrosine kinase reveals differences in on - and off - target inhibition
Albert Liclican et al.
BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS (2020)
Oral cedazuridine/decitabine for MDS and CMML: a phase 2 pharmacokinetic/pharmacodynamic randomized crossover study
Guillermo Garcia-Manero et al.
BLOOD (2020)
Advances in Long-Acting Agents for the Treatment of HIV Infection
Aadia I. Rana et al.
DRUGS (2020)
Sacituzumab govitecan, a novel, third-generation, antibody-drug conjugate (ADC) for cancer therapy
David M. Goldenberg et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2020)
Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: a multicentre, phase 2 trial
Yunpeng Yang et al.
LANCET RESPIRATORY MEDICINE (2020)
Synthetic Approaches to New Drugs Approved during 2018
Andrew C. Flick et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Oral Azacitidine and Cedazuridine Approximate Parenteral Azacitidine Efficacy in Murine Model
Haley E. Ramsey et al.
TARGETED ONCOLOGY (2020)
Open-label, long-term extension study to evaluate the safety of clascoterone (CB-03-01) cream, 1% twice daily, in patients with acne vulgaris
Lawrence Eichenfield et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2020)
Efficacy and Safety of Topical Clascoterone Cream, 1%, for Treatment in Patients With Facial Acne Two Phase 3 Randomized Clinical Trials
Adelaide Hebert et al.
JAMA DERMATOLOGY (2020)
Preclinical Activity of HER2-Selective Tyrosine Kinase Inhibitor Tucatinib as a Single Agent or in Combination with Trastuzumab or Docetaxel in Solid Tumor Models
Anita Kulukian et al.
MOLECULAR CANCER THERAPEUTICS (2020)
Fostemsavir in Adults with Multidrug-Resistant HIV-1 Infection
Michael Kozal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Cabotegravir Plus Rilpivirine: First Approval
A. Markham
DRUGS (2020)
New drug approvals for 2019: Synthesis and clinical applications
Shuo Yuan et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)
Current knowledge about the antivirals remdesivir (GS-5734) and GS-441524 as therapeutic options for coronaviruses
E. Susan Amirian et al.
ONE HEALTH (2020)
Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial
Michael C Heinrich et al.
LANCET ONCOLOGY (2020)
Coblopasvir and sofosbuvir for treatment of chronic hepatitis C virus infection in China: A single-arm, open-label, phase 3 trial
Yanhang Gao et al.
LIVER INTERNATIONAL (2020)
Discovery of Dotinurad (FYU-981), a New Phenol Derivative with Highly Potent Uric Acid Lowering Activity
Junichiro Uda et al.
ACS MEDICINAL CHEMISTRY LETTERS (2020)
Efficacy and safety of HIF prolyl-hydroxylase inhibitor vs epoetin and darbepoetin for anemia in chronic kidney disease patients not undergoing dialysis: A network meta-analysis
Qiyan Zheng et al.
PHARMACOLOGICAL RESEARCH (2020)
Recent Advances in the Treatment of Patients with Multiple Myeloma
Mario A. Legarda et al.
CANCERS (2020)
The role of belantamab mafodotin for patients with relapsed and/or refractory multiple myeloma
Melody R. Becnel et al.
THERAPEUTIC ADVANCES IN HEMATOLOGY (2020)
Levonadifloxacin arginine salt to treat acute bacterial skin and skin structure infection due to S. aureus including MRSA
D. Saxena et al.
DRUGS OF TODAY (2020)
A Scalable Total Synthesis of the Antitumor Agents Et-743 and Lurbinectedin
Weiming He et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2019)
Review of Synthetic Routes and Final Forms of Integrase Inhibitors Dolutegravir, Cabotegravir, and Bictegravir
David L. Hughes
ORGANIC PROCESS RESEARCH & DEVELOPMENT (2019)
APOLLO-1: a randomized placebo and active-controlled phase III study investigating oliceridine (TRV130), a G protein-biased ligand at the μ-opioid receptor, for management of moderate-to-severe acute pain following bunionectomy
Eugene R. Viscusi et al.
JOURNAL OF PAIN RESEARCH (2019)
Synthetic Approaches to the New Drugs Approved During 2017
Andrew C. Flick et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
New Synthetic Route to Tucatinib
Lingfeng Yin et al.
SYNTHESIS-STUTTGART (2019)
APOLLO-2: A Randomized, Placebo and Active-Controlled Phase III Study Investigating Oliceridine (TRV130), a G Protein-Biased Ligand at the μ-Opioid Receptor, for Management of Moderate to Severe Acute Pain Following Abdominoplasty
Neil K. Singla et al.
PAIN PRACTICE (2019)
Hypoxia-Inducible Factor Activators in Renal Anemia: Current Clinical Experience
Neil S. Sanghani et al.
ADVANCES IN CHRONIC KIDNEY DISEASE (2019)
Lurbinectedin synergizes with immune checkpoint blockade to generate anticancer immunity
Wei Xie et al.
ONCOIMMUNOLOGY (2019)
Reversible binding of the anticancer drug KXO1 (tirbanibulin) to the colchicine-binding site of ?-tubulin explains KXO1's low clinical toxicity
Lu Niu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2019)
Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial
Jeffrey A. Cohen et al.
LANCET NEUROLOGY (2019)
ATHENA: A Phase 3, Open-Label Study Of The Safety And Effectiveness Of Oliceridine (TRV130), A G-Protein Selective Agonist At The μ-Opioid Receptor, In Patients With Moderate To Severe Acute Pain Requiring Parenteral Opioid Therapy
Sergio D. Bergese et al.
JOURNAL OF PAIN RESEARCH (2019)
The importance of synthetic chemistry in the pharmaceutical industry
Kevin R. Campos et al.
SCIENCE (2019)
Levonadifloxacin, a Novel Broad-Spectrum Anti-MRSA Benzoquinolizine Quinolone Agent: Review of Current Evidence
Sachin S. Bhagwat et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2019)
Efficacy and Safety of All-oral, 12-week Ravidasvir Plus Ritonavir-boosted Danoprevir and Ribavirin in Treatment-naive Noncirrhotic HCV Genotype 1 Patients: Results from a Phase 2/3 Clinical Trial in China
Xiaoyuan Xu et al.
JOURNAL OF CLINICAL AND TRANSLATIONAL HEPATOLOGY (2019)
A Placebo-Controlled, Randomized Trial of Enarodustat in Patients with Chronic Kidney Disease Followed by Long-Term Trial
Tadao Akizawa et al.
AMERICAN JOURNAL OF NEPHROLOGY (2019)
Long-Acting Anti-HIV Drugs Targeting HIV-1 Reverse Transcriptase and Integrase
Kamal Singh et al.
PHARMACEUTICALS (2019)
Hereditary angioedema: Linking complement regulation to the coagulation system
Marcel Levi et al.
RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS (2019)
Inhibitors of HIV-1 Attachment: The Discovery and Development of Temsavir and its Prodrug Fostemsavir
Nicholas A. Meanwell et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Ensartinib (X-396) in ALK-Positive Non-Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study
Leora Horn et al.
CLINICAL CANCER RESEARCH (2018)
New urate-lowing therapies
Abhishek Abhishek
CURRENT OPINION IN RHEUMATOLOGY (2018)
Background and rationale of the eXalt3 tria investigating X-396 in the treatment of ALK plus non-small-cell lung cancer
Eric K. Singhi et al.
FUTURE ONCOLOGY (2018)
Synthetic Approaches to New Drugs Approved During 2016
Andrew C. Flick et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Discovery of Novel Dual Mechanism of Action Src Signaling and Tubulin Polymerization Inhibitors (KX2-391 and KX2-361)
Michael P. Smolinski et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Prolyl Hydroxylase Inhibitors: A Breakthrough in the Therapy of Anemia Associated with Chronic Diseases
Amit A. Joharapurkar et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Discovery of the Human Immunodeficiency Virus Type 1 (HIV-1) Attachment Inhibitor Temsavir and Its Phosphonooxymethyl Prodrug Fostemsavir
Tao Wang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Chemical probes and drug leads from advances in synthetic planning and methodology
Christopher J. Gerry et al.
NATURE REVIEWS DRUG DISCOVERY (2018)
Clinical studies evaluating abametapir lotion, 0.74%, for the treatment of head louse infestation
Vernon M. Bowles et al.
PEDIATRIC DERMATOLOGY (2018)
Discovery of Risdiplam, a Selective Survival of Motor Neuron-2 (SMN2) Gene Splicing Modifier for the Treatment of Spinal Muscular Atrophy (SMA)
Hasane Ratni et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Emerging EZH2 Inhibitors and Their Application in Lymphoma
Jennifer K. Lue et al.
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2018)
Silicon-containing analogs of camptothecin as anticancer agents
Nataliya F. Lazareva et al.
ARCHIV DER PHARMAZIE (2018)
Effects of Daprodustat, a Novel Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor on Anemia Management in Japanese Hemodialysis Subjects
Tadao Akizawa et al.
AMERICAN JOURNAL OF NEPHROLOGY (2017)
Filgotinib (GLPG0634/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2)
A. Kavanaugh et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1)
R. Westhovens et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Ovicidal Efficacy of Abametapir Against Eggs of Human Head and Body Lice (Anoplura: Pediculidae)
Vernon M. Bowles et al.
JOURNAL OF MEDICAL ENTOMOLOGY (2017)
Safe approaches for camptothecin delivery: Structural analogues and nanomedicines
Pablo Botella et al.
JOURNAL OF CONTROLLED RELEASE (2017)
Synthetic Approaches to the New Drugs Approved During 2015
Andrew C. Flick et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
Discovery and Synthesis of a Phosphoramidate Prodrug of a Pyrrolo(2,1-f][triazin-4-amino] Adenine C-Nucleoside (GS-5734) for the Treatment of Ebola and Emerging Viruses
Dustin Siegel et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
Discovery and Preclinical Characterization of GSK1278863 (Daprodustat), a Small Molecule Hypoxia Inducible Factor-Prolyl Hydroxylase Inhibitor for Anemias
Jennifer L. Ariazi et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2017)
The race to target MET exon 14 skipping alterations in non-small cell lung cancer: The Why, the How, the Who, the Unknown, and the Inevitable
Thanyanan Reungwetwattana et al.
LUNG CANCER (2017)
Preparation of the HIV Attachment Inhibitor BMS-663068. Part 4. Synthesis of the 6-Azaindole Core
Michael S. Bultman et al.
ORGANIC PROCESS RESEARCH & DEVELOPMENT (2017)
Preparation of the HIV Attachment Inhibitor BMS-663068. Part 5. Selective C-7 Bromination of the 6-Azaindole Core
Francisco Gonzalez-Bobes et al.
ORGANIC PROCESS RESEARCH & DEVELOPMENT (2017)
Preparation of the HIV Attachment Inhibitor BMS-663068. Part 3. Mechanistic Studies Enable a Scale-Independent Friedel-Crafts Acylation
Gregory L. Beutner et al.
ORGANIC PROCESS RESEARCH & DEVELOPMENT (2017)
Preparation of the HIV Attachment Inhibitor BMS-663068. Part 2. Strategic Selections in the Transition from an Enabling Route to a Commercial Synthesis
Ke Chen et al.
ORGANIC PROCESS RESEARCH & DEVELOPMENT (2017)
Preparation of the HIV Attachment Inhibitor BMS-663068. Part 6. Friedel Crafts Acylation/Hydrolysis and Amidation
Bin Zheng et al.
ORGANIC PROCESS RESEARCH & DEVELOPMENT (2017)
Preparation of the HIV Attachment Inhibitor BMS-663068. Part 1. Evolution of Enabling Strategies
Richard J. Fox et al.
ORGANIC PROCESS RESEARCH & DEVELOPMENT (2017)
Preparation of the HIV Attachment Inhibitor BMS-663068. Part 7. Development of a Regioselective Ullmann-Goldberg-Buchwald Reaction
William P. Gallagher et al.
ORGANIC PROCESS RESEARCH & DEVELOPMENT (2017)
Preparation of the HIV Attachment Inhibitor BMS-663068. Part 8. Installation of the Phosphonoxymethyl Prodrug Moiety
Richard J. Fox et al.
ORGANIC PROCESS RESEARCH & DEVELOPMENT (2017)
Preparation of the HIV Attachment Inhibitor BMS-663068. Part 9. Active Pharmaceutical Ingredient Process Development and Powder Properties
Thomas E. La Cruz et al.
ORGANIC PROCESS RESEARCH & DEVELOPMENT (2017)
Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses
Timothy P. Sheahan et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
Total Synthesis of Camptothecins: An Update
Lei Chen et al.
SYNLETT (2017)
Discovery of JTZ-951: A HIF Prolyl Hydroxylase Inhibitor for the Treatment of Renal Anemia
Yosuke Ogoshi et al.
ACS MEDICINAL CHEMISTRY LETTERS (2017)
Lesinurad, a Selective Uric Acid Reabsorption Inhibitor, in Combination With Febuxostat in Patients With Tophaceous Gout Findings of a Phase III Clinical Trial
Nicola Dalbeth et al.
ARTHRITIS & RHEUMATOLOGY (2017)
Poorly controlled postoperative pain: prevalence, consequences, and prevention
Tong J. Gan
JOURNAL OF PAIN RESEARCH (2017)
GS-5734 and its parent nucleoside analog inhibit Filo-, Pneumo-, and Paramyxoviruses
Michael K. Lo et al.
SCIENTIFIC REPORTS (2017)
Lurbinectedin reduces tumour-associated macrophages and the inflammatory tumour microenvironment in preclinical models
Cristina Belgiovine et al.
BRITISH JOURNAL OF CANCER (2017)
Advances and challenges in targeting FGFR signalling in cancer
Irina S. Babina et al.
NATURE REVIEWS CANCER (2017)
Analysis of Past and Present Synthetic Methodologies on Medicinal Chemistry: Where Have All the New Reactions Gone?
Dean G. Brow et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
Synthetic approaches to the 2014 new drugs
Andrew C. Flick et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2016)
Synthetic approaches to the 2010-2014 new agrochemicals
Stephane Jeanmart et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2016)
Discovery of ravidasvir (PPI-668) as a potent pan-genotypic HCV NS5A inhibitor
Min Zhong et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2016)
Ozanimod (RPC1063) is a potent sphingosine-1-phosphate receptor-1 (S1P1) and receptor-5 (S1P5) agonist with autoimmune disease-modifying activity
F. L. Scott et al.
BRITISH JOURNAL OF PHARMACOLOGY (2016)
10-Boronic acid substituted camptothecin as prodrug of SN-38
Lei Wang et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2016)
Second-generation inhibitors of Bruton tyrosine kinase
Jingjing Wu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2016)
Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys
Travis K. Warren et al.
NATURE (2016)
Reinventing Chemistry
George M. Whitesides
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2015)
Synthetic approaches to the 2013 new drugs
Hong X. Ding et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2015)
Identification and optimization of pyridazinones as potent and selective c-Met kinase inhibitors
Dieter Dorsch et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2015)
An Efficient and Highly Diastereoselective Synthesis of GSK1265744, a Potent HIV Integrase Inhibitor
Huan Wang et al.
ORGANIC LETTERS (2015)
Pharmacological properties of JTE-052: a novel potent JAK inhibitor that suppresses various inflammatory responses in vitro and in vivo
Atsuo Tanimoto et al.
INFLAMMATION RESEARCH (2015)
Synthetic approaches to the 2012 new drugs
Hong X. Ding et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2014)
Advancing Antibody Drug Conjugation From the Laboratory to a Clinically Approved Anticancer Drug
Nicole M. Okeley et al.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2014)
Pharmacokinetics, Safety, and Tolerability With Repeat Doses of GSK1265744 and Rilpivirine (TMC278) Long-Acting Nanosuspensions in Healthy Adults
William Spreen et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2014)
Design, Synthesis, and Pharmacological Evaluation of Fluorinated Tetrahydrouridine Derivatives as Inhibitors of Cytidine Deaminase
Dana Ferraris et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Discovery of Ledipasvir (GS-5885): A Potent, Once-Daily Oral NS5A Inhibitor for the Treatment of Hepatitis C Virus Infection
John O. Link et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Triazolopyridines as Selective JAK1 Inhibitors: From Hit Identification to GLPG0634
Christel J. Menet et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Discovery and Development of Hepatitis C Virus NS5A Replication Complex Inhibitors
Makonen Belema et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Hepatitis C Virus NS5A Replication Complex Inhibitors: The Discovery of Daclatasvir
Makonen Belema et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Discovery of Daclatasvir, a Pan-Genotypic Hepatitis C Virus NS5A Replication Complex Inhibitor with Potent Clinical Effect
Makonen Belema et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Selective Inhibition of EZH2 by EPZ-6438 Leads to Potent Antitumor Activity in EZH2-Mutant Non-Hodgkin Lymphoma
Sarah K. Knutson et al.
MOLECULAR CANCER THERAPEUTICS (2014)
CALCITONIN GENE-RELATED PEPTIDE: PHYSIOLOGY AND PATHOPHYSIOLOGY
F. A. Russell et al.
PHYSIOLOGICAL REVIEWS (2014)
The NF1 gene revisited - from bench to bedside
Yoon-Sim Yap et al.
ONCOTARGET (2014)
Antibody-Drug Conjugates in Cancer Therapy
Eric L. Sievers et al.
ANNUAL REVIEW OF MEDICINE, VOL 64 (2013)
Synthetic approaches to the 2011 new drugs
Hong X. Ding et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2013)
Farnesyltransferase Inhibitors: A Comprehensive Review Based on Quantitative Structural Analysis
N. S. H. N. Moorthy et al.
CURRENT MEDICINAL CHEMISTRY (2013)
Preclinical Characterization of GLPG0634, a Selective Inhibitor of JAK1, for the Treatment of Inflammatory Diseases
Luc Van Rompaey et al.
JOURNAL OF IMMUNOLOGY (2013)
Carbamoyl Pyridone HIV-1 Integrase Inhibitors 3. A Diastereomeric Approach to Chiral Nonracemic Tricyclic Ring Systems and the Discovery of Dolutegravir (S/GSK1349572) and (S/GSK1265744)
Brian A. Johns et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
Structure Activity Relationships and Discovery of a G Protein Biased μ Opioid Receptor Ligand, [(3-Methoxythiophen-2-yl)methyl]a2[(9R)-9-(pyridin-2-y1)-6-oxaspiro-[4.5]clecan-9-yl]ethylpamine (TRV130), for the Treatment of Acute Severe Pain
Xiao-Tao Chen et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
Neurologic features of Hutchinson-Gilford progeria syndrome after lonafarnib treatment
Nicole J. Ullrich et al.
NEUROLOGY (2013)
SCALABLE SYNTHETIC ROUTE TO 2-AMINO-5HYDROXYPROPIOPHENONE: EFFICIENT FORMAL SYNTHESIS OF IRINOTECAN
A. V. Rama Rao et al.
SYNTHETIC COMMUNICATIONS (2013)
Discovery and in Vivo Evaluation of Potent Dual CYP11B2 (Aldosterone Synthase) and CYP11B1 Inhibitors
Erik L. Meredith et al.
ACS MEDICINAL CHEMISTRY LETTERS (2013)
EASILY MISSED? Cushing's syndrome
Julia Kate Prague et al.
BMJ-BRITISH MEDICAL JOURNAL (2013)
Synthetic approaches to the 2010 new drugs
Kevin K. -C. Liu et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2012)
Calcitonin gene-related peptide (CGRP) receptor antagonists: Pyridine as a replacement for a core amide group
Guanglin Luo et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2012)
Hyperuricemia, gout and the kidney
Terence Gibson
CURRENT OPINION IN RHEUMATOLOGY (2012)
Discovery of (5S,6S,9R)-5-Amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-yl 4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxylate (BMS-927711): An Oral Calcitonin Gene-Related Peptide (CGRP) Antagonist in Clinical Trials for Treating Migraine
Guanglin Luo et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
Total Synthesis of Camptothecin and SN-38
Shanbao Yu et al.
JOURNAL OF ORGANIC CHEMISTRY (2012)
Efficient and Scalable Enantioselective Synthesis of a CGRP Antagonist
David K. Leahy et al.
ORGANIC LETTERS (2012)
Development of Two Complementary Syntheses for a Privileged CGRP Receptor Antagonist Substructure
David K. Leahy et al.
ORGANIC PROCESS RESEARCH & DEVELOPMENT (2012)
The enumeration of chemical space
Jean-Louis Reymond et al.
WILEY INTERDISCIPLINARY REVIEWS-COMPUTATIONAL MOLECULAR SCIENCE (2012)
Synthetic approaches to the 2009 new drugs
Kevin K. -C. Liu et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2011)
Total Synthesis of 7-Ethyl-10-hydroxycamptothecin (SN38) and its Application to the Development of C18-Functionalized Camptothecin Derivatives
Yuan-Shan Yao et al.
CHEMISTRY-A EUROPEAN JOURNAL (2011)
A Novel Iodide-Catalyzed Reduction of Nitroarenes and Aryl Ketones with H3PO2 or H3PO3: Its Application to the Synthesis of a Potential Anticancer Agent
George G. Wu et al.
ORGANIC LETTERS (2011)
PM01183, a new DNA minor groove covalent binder with potent in vitro and in vivo anti-tumour activity
J. F. M. Leal et al.
BRITISH JOURNAL OF PHARMACOLOGY (2010)
Synthetic Studies on Camptothecins Part 3 Total Synthesis of (20S)-7-Ethyl-10-hydroxycamptothecin via a Bifunctional Thiourea-Based Cinchona Alkaloid-Mediated Enantioselective Cyanosilylation Strategy
Yun-Yan Kuang et al.
HELVETICA CHIMICA ACTA (2010)
Synthetic Approaches to the 2008 New Drugs
Kevin K.-C. Liu et al.
MINI-REVIEWS IN MEDICINAL CHEMISTRY (2010)
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer.
Juan Valle et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Synthesis of sulfonamide-based kinase inhibitors from sulfonates by exploiting the abrogated S(N)2 reactivity of 2,2,2-trifluoroethoxysulfonates
Christopher Wong et al.
ORGANIC & BIOMOLECULAR CHEMISTRY (2010)
Is there a Future for Organic Chemists in the Pharmaceutical Industry outside China and India?
Trevor Laird
ORGANIC PROCESS RESEARCH & DEVELOPMENT (2010)
Manufacturing synthesis of 5-hydroxy-2-methyl-1H-indole
Yun-Sheng Huang et al.
RESEARCH ON CHEMICAL INTERMEDIATES (2010)
A new approach to the synthesis of L-3-hydroxy-4-methoxy-5-methyl-phenylalanine derivatives from L-tyrosine
Ruijiao Chen et al.
TETRAHEDRON-ASYMMETRY (2010)
Preparation, Use, and Safety of O-Mesitylenesulfonylhydroxylamine
Javier Mendiola et al.
ORGANIC PROCESS RESEARCH & DEVELOPMENT (2009)
Synthetic approaches to homocamptothecin antitumor agents
Dennis P. Curran
COMPTES RENDUS CHIMIE (2008)
Design, synthesis and development of novel camptothecin drugs
Siong Tern Liew et al.
CURRENT PHARMACEUTICAL DESIGN (2008)
Antibody Conjugates of 7-Ethyl-10-hydroxycamptothecin (SN-38) for Targeted Cancer Chemotherapy
Sung-Ju Moon et al.
JOURNAL OF MEDICINAL CHEMISTRY (2008)
Synthetic Approaches to the 2007 New Drugs
Kevin K. -C. Liu et al.
MINI-REVIEWS IN MEDICINAL CHEMISTRY (2008)
Lipase-catalyzed preparation of corticosteroid 17α-esters endowed with antiandrogenic activity
Patrizia Ferraboschi et al.
TETRAHEDRON LETTERS (2008)
Synthetic approaches to the 2006 new drugs
Kevin K. -C. Liu et al.
MINI-REVIEWS IN MEDICINAL CHEMISTRY (2007)
Synthetic approaches to the 2005 new drugs
Subas M. Sakya et al.
MINI-REVIEWS IN MEDICINAL CHEMISTRY (2007)
Ozonolysis applications in drug synthesis
Scott G. Van Ornum et al.
CHEMICAL REVIEWS (2006)
Transport mechanism-based drug molecular design: Novel camptothecin analogues to circumvent ABCG2-associated drug resistance of human tumor cells
T Ishikawa et al.
CURRENT PHARMACEUTICAL DESIGN (2006)
Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: Effects of linker technology on efficacy and toxicity
SO Doronina et al.
BIOCONJUGATE CHEMISTRY (2006)
Synthetic approaches to the 2004 new drugs
J Li et al.
MINI-REVIEWS IN MEDICINAL CHEMISTRY (2005)
Synthesis and pharmacology of new camptothecin drugs
RW Driver et al.
MINI-REVIEWS IN MEDICINAL CHEMISTRY (2005)
14-azacamptothecin: A potent water-soluble topoisomerase I poison
KJ Cheng et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2005)
Timeline - The discovery of receptor tyrosine kinases: targets for cancer therapy
A Gschwind et al.
NATURE REVIEWS CANCER (2004)
Camptothecin: current perspectives
CJ Thomas et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2004)
Synthetic approaches to the 2002 new drugs
J Li et al.
MINI-REVIEWS IN MEDICINAL CHEMISTRY (2004)
An efficient one-pot process for 10-bromo-8-chloro-5,6-dihydro-benzo[5,6]cyclohepta[1,2-b]pyridin-11-one, an intermediate to SCH 66336
XY Fu et al.
ORGANIC PROCESS RESEARCH & DEVELOPMENT (2003)
A novel enantioselective alkylation and its application to the synthesis of an anticancer agent
SC Kuo et al.
JOURNAL OF ORGANIC CHEMISTRY (2003)
Worldwide trends in mortality from biliary tract malignancies
T Patel
BMC CANCER (2002)
Selective activation of anticancer prodrugs by monoclonal antibody-enzyme conjugates
PD Senter et al.
ADVANCED DRUG DELIVERY REVIEWS (2001)
An anion-induced regio- and chemoselective acylation and its application to the synthesis of an anticancer agent
M Poirier et al.
ORGANIC LETTERS (2001)
Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma
WR Jarnagin et al.
ANNALS OF SURGERY (2001)
分享论文
